Vanguard Capital Wealth Advisors Acquires 50 Shares of Eli Lilly and Company (NYSE:LLY)

Vanguard Capital Wealth Advisors increased its holdings in Eli Lilly and Company (NYSE:LLY) by 10.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 545 shares of the company’s stock after buying an additional 50 shares during the period. Vanguard Capital Wealth Advisors’ holdings in Eli Lilly and Company were worth $318,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of LLY. Mission Wealth Management LP grew its holdings in Eli Lilly and Company by 0.4% during the fourth quarter. Mission Wealth Management LP now owns 7,213 shares of the company’s stock valued at $4,204,000 after purchasing an additional 26 shares during the period. Stonebridge Financial Planning Group LLC grew its holdings in Eli Lilly and Company by 135.0% during the fourth quarter. Stonebridge Financial Planning Group LLC now owns 1,034 shares of the company’s stock valued at $603,000 after purchasing an additional 594 shares during the period. Certuity LLC grew its holdings in Eli Lilly and Company by 319.3% during the fourth quarter. Certuity LLC now owns 9,933 shares of the company’s stock valued at $5,790,000 after purchasing an additional 7,564 shares during the period. Penobscot Investment Management Company Inc. grew its holdings in Eli Lilly and Company by 9.5% during the fourth quarter. Penobscot Investment Management Company Inc. now owns 6,380 shares of the company’s stock valued at $3,719,000 after purchasing an additional 552 shares during the period. Finally, Duff & Phelps Investment Management Co. grew its holdings in Eli Lilly and Company by 1.0% during the fourth quarter. Duff & Phelps Investment Management Co. now owns 8,904 shares of the company’s stock valued at $5,190,000 after purchasing an additional 90 shares during the period. 82.53% of the stock is owned by institutional investors.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on LLY. Truist Financial reissued a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. BMO Capital Markets raised their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Barclays raised their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Bank of America raised their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $731.55.

Eli Lilly and Company Stock Up 6.0 %

Eli Lilly and Company stock traded up $44.36 during trading hours on Tuesday, hitting $781.56. 7,432,651 shares of the stock traded hands, compared to its average volume of 3,071,009. The firm’s 50-day moving average price is $760.89 and its two-hundred day moving average price is $668.00. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market cap of $742.61 billion, a PE ratio of 134.43, a PEG ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a one year low of $392.26 and a one year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.09 EPS. On average, research analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.